Suppr超能文献

小非编码RNA:它们能为未来控制新型冠状病毒提供答案吗?

Small Non-coding RNAs: Do They Encode Answers for Controlling SARS-CoV-2 in the Future?

作者信息

Bhattacharyya Pallabi, Biswas Subhas C

机构信息

Cell Biology & Physiology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.

出版信息

Front Microbiol. 2020 Sep 18;11:571553. doi: 10.3389/fmicb.2020.571553. eCollection 2020.

Abstract

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel coronavirus responsible for the current COVID-19 (coronavirus disease 2019) pandemic, which has hit the world since December 2019. It has spread to about 216 countries worldwide, affecting more than 21.7 million people so far. Although clinical trials of a number of promising antiviral drugs and vaccines against COVID-19 are underway, it is hard to predict how successful these drug- or vaccine-based therapeutics are eventually going to be in combating COVID-19 because most of such therapeutic strategies have failed against human coronaviruses such as SARS-CoV and MERS-CoV (Middle East respiratory syndrome coronavirus) responsible for similar pandemics in the past. In that context, we would like to bring to scientific attention another group of endogenous regulatory molecules, the small non-coding RNAs, especially the microRNAs, which are found to regulate critical cellular pathways in a number of disease conditions, including RNA viral infections. This review will focus on understanding the effect of altered microRNA expression during coronavirus-mediated infections and how it may provide clues for further exploring the pathogenesis of SARS-CoV-2, with a view of developing RNAi-based therapeutics and biomarkers against COVID-19.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是一种新型冠状病毒,引发了自2019年12月以来席卷全球的2019冠状病毒病(COVID-19)大流行。它已传播到全球约216个国家,迄今感染人数超过2170万。尽管针对COVID-19的一些有前景的抗病毒药物和疫苗的临床试验正在进行,但很难预测这些基于药物或疫苗的治疗方法最终在对抗COVID-19方面会取得多大成功,因为过去大多数此类治疗策略在对抗诸如导致类似大流行的严重急性呼吸综合征冠状病毒(SARS-CoV)和中东呼吸综合征冠状病毒(MERS-CoV)等人类冠状病毒时均告失败。在此背景下,我们希望引起科学界对另一组内源性调节分子——小非编码RNA,尤其是微小RNA的关注,它们在包括RNA病毒感染在内的多种疾病状态下调节关键细胞通路。本综述将着重于了解冠状病毒介导的感染过程中微小RNA表达改变的影响,以及这如何为进一步探索SARS-CoV-2的发病机制提供线索,以期开发出针对COVID-19的基于RNA干扰的治疗方法和生物标志物。

相似文献

1
Small Non-coding RNAs: Do They Encode Answers for Controlling SARS-CoV-2 in the Future?
Front Microbiol. 2020 Sep 18;11:571553. doi: 10.3389/fmicb.2020.571553. eCollection 2020.
2
Current Strategies of Antiviral Drug Discovery for COVID-19.
Front Mol Biosci. 2021 May 13;8:671263. doi: 10.3389/fmolb.2021.671263. eCollection 2021.
3
Human and novel coronavirus infections in children: a review.
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
4
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Drug Resist Updat. 2020 Dec;53:100721. doi: 10.1016/j.drup.2020.100721. Epub 2020 Aug 26.
5
COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far.
Molecules. 2020 Dec 23;26(1):39. doi: 10.3390/molecules26010039.
6
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
Front Immunol. 2020 Aug 19;11:1880. doi: 10.3389/fimmu.2020.01880. eCollection 2020.
7
SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.
Bol Med Hosp Infant Mex. 2020;77(5):252-261. doi: 10.24875/BMHIM.20000191.
8
Potential Drug Strategies to Target Coronaviruses.
Adv Exp Med Biol. 2021;1352:111-124. doi: 10.1007/978-3-030-85109-5_7.
9
SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.
Ann Clin Microbiol Antimicrob. 2020 Sep 2;19(1):40. doi: 10.1186/s12941-020-00384-w.
10
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19.
Drugs. 2021 Apr;81(5):517-531. doi: 10.1007/s40265-021-01474-5. Epub 2021 Feb 27.

引用本文的文献

1
Small non-coding RNAs encoded by RNA viruses: old controversies and new lessons from the COVID-19 pandemic.
Front Genet. 2023 Jun 21;14:1216890. doi: 10.3389/fgene.2023.1216890. eCollection 2023.
3
Nitazoxanide and COVID-19: A review.
Mol Biol Rep. 2022 Nov;49(11):11169-11176. doi: 10.1007/s11033-022-07822-2. Epub 2022 Sep 12.
4
Implications at the ocular level of miRNAs modifications induced by SARS-CoV-2 infection.
Rom J Morphol Embryol. 2022 Jan-Mar;63(1):55-59. doi: 10.47162/RJME.63.1.05.
7
MicroRNA-Mediated Regulation of the Virus Cycle and Pathogenesis in the SARS-CoV-2 Disease.
Int J Mol Sci. 2021 Dec 7;22(24):13192. doi: 10.3390/ijms222413192.
8
MicroRNA of N-region from SARS-CoV-2: Potential sensing components for biosensor development.
Biotechnol Appl Biochem. 2022 Aug;69(4):1696-1711. doi: 10.1002/bab.2239. Epub 2021 Aug 22.
9
Human MicroRNAs Interacting With SARS-CoV-2 RNA Sequences: Computational Analysis and Experimental Target Validation.
Front Genet. 2021 Jun 7;12:678994. doi: 10.3389/fgene.2021.678994. eCollection 2021.
10

本文引用的文献

1
On the origin and continuing evolution of SARS-CoV-2.
Natl Sci Rev. 2020 Jun;7(6):1012-1023. doi: 10.1093/nsr/nwaa036. Epub 2020 Mar 3.
2
microRNAs in viral acute respiratory infections: immune regulation, biomarkers, therapy, and vaccines.
ExRNA. 2019;1(1):1. doi: 10.1186/s41544-018-0004-7. Epub 2019 Feb 14.
4
Geographic and Genomic Distribution of SARS-CoV-2 Mutations.
Front Microbiol. 2020 Jul 22;11:1800. doi: 10.3389/fmicb.2020.01800. eCollection 2020.
5
ACE2, Much More Than Just a Receptor for SARS-COV-2.
Front Cell Infect Microbiol. 2020 Jun 5;10:317. doi: 10.3389/fcimb.2020.00317. eCollection 2020.
6
Computational analysis of microRNA-mediated interactions in SARS-CoV-2 infection.
PeerJ. 2020 Jun 5;8:e9369. doi: 10.7717/peerj.9369. eCollection 2020.
8
COVID-19 Virulence in Aged Patients Might Be Impacted by the Host Cellular MicroRNAs Abundance/Profile.
Aging Dis. 2020 May 9;11(3):509-522. doi: 10.14336/AD.2020.0428. eCollection 2020 May.
9
Implication of SARS-CoV-2 evolution in the sensitivity of RT-qPCR diagnostic assays.
Lancet Infect Dis. 2021 Feb;21(2):166-167. doi: 10.1016/S1473-3099(20)30435-7. Epub 2020 May 28.
10
Genomics functional analysis and drug screening of SARS-CoV-2.
Genes Dis. 2020 Dec;7(4):542-550. doi: 10.1016/j.gendis.2020.04.002. Epub 2020 Apr 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验